US4396601A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Gene transfer in intact mammals
Assignee: University of California Berkeley
•
Filing: 1980-03-26
•
Granted: 1983-08-02
•
Expires: 2000-03-26
Abstract
Abstract Methods and compositions are provided for gene transfer to intact mammals with expression of the exogenous genetic material in the host. Mammalian host cells which are regenerative, normally highly proliferative or subject to induced proliferation, are transformed or modified in vitro with DNA capable of replication and expression in the host cell, wherein the DNA becomes incorporated into the cell. The modified cells are found to regenerate in the host with expression of the introduced DNA. Particularly, mammalian cells were modified with genes providing for overproduction of a particular enzyme. The modified cells were reintroduced in the host under conditions providing for selective advantage of the modified cells.
Inventors
- 👤 Winston A. Salser
- 👤 Martin J. Cline
- 👤 Howard D. Stang
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 02:23
CPC Classifications
A; A01; A01K; A01K67/00; A01K67/027; A01K67/0275; A01K2217/00; A01K2217/05
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
139 words
A method for introducing into a mammalian host exogenous genetic capability capable of expression in said host, which comprises: isolating cells from a mammal or a syngeneic equivalent, where cells are from a regenerative body member to provide parent cells; combining said parent cells with DNA, including at least one gene capable of providing a selective advantage over the parent cells, when said parent cells are subjected to mitotic inhibition, under conditions where said DNA is introduced into said parent cells by other than cell-cell fusion to provide modified cells; introducing said modified cells into said host, wherein said modified cells return to said body member of said parent cells; and administering to said host said mitotic inhibitor to provide a selective advantage for said modified cells over said parent cells, whereby said modified cells regenerate in said host.
Claim 2
Independent Claim
139 words
A method for introducing into a mammalian host exogenous genetic capability capable of expression in said host, which comprises: isolating cells from a mammal or a syngeneic equivalent, where cells are from a regenerative body member to provide parent cells; combining said parent cells with DNA, including at least one gene capable of providing a selective advantage over the parent cells, when said parent cells are subjected to mitotic inhibition, under conditions where said DNA is introduced into said parent cells by other than cell-cell fusion to provide modified cells; introducing said modified cells into said host, wherein said modified cells return to said body member of said parent cells; and administering to said host said mitotic inhibitor to provide a selective advantage for said modified cells over said parent cells, whereby said modified cells regenerate in said host.
Claim 3
Dependent Claim
31 words
A method according to claim 1, wherein the host or syngeneic member is subjected to growth inhibition prior to removing said parent cells to provide for cells in the dividing phase.
Claim 4
Independent Claim
17 words
A method according to claims 1 or 2, wherein said parent cells are bone marrow stem cells.
Claim 5
Dependent Claim
19 words
A method according to claim 3, wherein said one gene capable of providing a selective advantage expresses an enzyme.
Claim 6
Dependent Claim
12 words
A method according to claim 4, wherein said enzyme is thymidine kinase.
Claim 7
Dependent Claim
21 words
A method according to claim 4, wherein said DNA includes at least one additional gene which expresses a wild type protein.
Claim 8
Dependent Claim
20 words
A method according to claim 4, wherein said one gene expressed as an enzyme is inhibited by said growth inhibitor.
Claim 9
Dependent Claim
14 words
A method according to claim 7, wherein said growth inhibitor is a chemotherapeutic drug.
Claim 10
Dependent Claim
20 words
A method according to claim 8, wherein said enzyme is dihydrofolate reductase and said growth inhibitor is methotrexate or 5-fluorouracil.
Claim 11
Independent Claim
36 words
A method according to any of claims 1 or 6, wherein said host has a genetic deficiency, and said DNA includes at least one wild type gene which expresses the normal protein for said host deficiency.
Claim 12
Independent Claim
101 words
A method for treating a host having a neoplasm, which comprises: removing bone marrow cells from said host or syngeneic member, where said cells are in a dividing phase; combining said bone marrow cells with DNA containing at least one gene capable of expressing an enzyme inhibited by a chemotherapeutic drug which inhibits mitosis, wherein said cells become modified with said DNA to produce modified cells; introducing said modified cells into said host, whereby said cells return to said bone marrow; and administering said mitotic inhibitor to said host, whereby said modified cells proliferate in the presence of said mitotic inhibitor.
Claim 13
Independent Claim
101 words
A method for treating a host having a neoplasm, which comprises: removing bone marrow cells from said host or syngeneic member, where said cells are in a dividing phase; combining said bone marrow cells with DNA containing at least one gene capable of expressing an enzyme inhibited by a chemotherapeutic drug which inhibits mitosis, wherein said cells become modified with said DNA to produce modified cells; introducing said modified cells into said host, whereby said cells return to said bone marrow; and administering said mitotic inhibitor to said host, whereby said modified cells proliferate in the presence of said mitotic inhibitor.
Claim 14
Dependent Claim
18 words
A method according to claim 11, wherein said enzyme is dihydrofolate reductase and said mitotic inhibitor is methotrexate.
Claim 15
Independent Claim
117 words
A method for introducing into a mammalian host exogenous genetic capability of expression in said host, which comprises: isolating cells from a mammal or a syngeneic member, where said cells are from a regenerative body member, to provide parent cells; combining said cells with DNA, including at least one gene capable of providing a selective advantage over the parent cells, where said gene is capable of expression of an enzyme of a biosynthetic pathway to a metabolite necessary for mitosis, under conditions where DNA is introduced into said parent cells to provide modified cells; introducing said modified cells into said host wherein said modified cells return to said body member of said parent cells and undergo regeneration.
Claim 16
Independent Claim
117 words
A method for introducing into a mammalian host exogenous genetic capability of expression in said host, which comprises: isolating cells from a mammal or a syngeneic member, where said cells are from a regenerative body member, to provide parent cells; combining said cells with DNA, including at least one gene capable of providing a selective advantage over the parent cells, where said gene is capable of expression of an enzyme of a biosynthetic pathway to a metabolite necessary for mitosis, under conditions where DNA is introduced into said parent cells to provide modified cells; introducing said modified cells into said host wherein said modified cells return to said body member of said parent cells and undergo regeneration.
Claim 17
Dependent Claim
13 words
A method according to claim 13, wherein said cells are bone marrow cells.
Claim 18
Independent Claim
16 words
A method according to any of claims 13 or 14, wherein said enzyme is thymidine kinase.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-08-01 | 1987-01-31 | 1987-08-02 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-08-01 | 1991-01-31 | 1991-08-02 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-08-01 | 1995-01-31 | 1995-08-02 | $7700.00 | Window Closed / Lapsed |